Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 29, 2024
Daily News
November 29, 2024
- DPP Head, Industry Leaders United towards Stopping Off-Year Price Revisions
November 29, 2024
- MOF Panel Urges Annual Price Revisions on All Drugs in 2025 Budget Proposal
November 29, 2024
- Japan Pharma Market Projected to Cross 12 Trillion Yen in FY2029: IQVIA
November 29, 2024
- Japan to Require Drug Makers to Set Up Legal Post of “Stable Supply Manager”
November 29, 2024
- Japan Set to Put Up 100 Billion Yen to Support Pharma under Economic Package
November 29, 2024
- Leqembi Now Available in South Korea: Eisai
November 29, 2024
- Orphan Tag Given to Renalys’ IgA Nephropathy Therapy and 13 More Drugs
November 29, 2024
- How to Be a Country Manager
November 29, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…